What's new? Log in Free sign up

Vaxcyte (PCVX)

Company Profile

Company profile

Ticker

PCVX

Exchange

Website

CEO

Mr. Grant E. Pickering M.B.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Moderna • Bio-Techne • Acorda Therapeutics • Mach Natural Resources ...

Former names

SutroVax, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries

Vaxcyte Switzerland GmbH ...

IRS number

464233385

PCVX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Entry into a Material Definitive Agreement

Quarterly report

5 Nov 24

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Regulation FD Disclosure

Quarterly report

6 Aug 24

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

Departure of Directors or Certain Officers

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

ANDREW GUGGENHIME

Notice of proposed sale of securities

Notice of proposed sale of securities

Mikhail Eydelman

Notice of proposed sale of securities

Notice of proposed sale of securities

ANDREW GUGGENHIME

Financial summary

Financial statements Chart PCVX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	1.05 bn	1.05 bn	1.05 bn	1.05 bn	1.05 bn	1.05 bn
Cash burn (monthly)	(no burn)	(no burn)	46.64 mm	50.34 mm	20.24 mm	39.17 mm
Cash used (since last report)	n/a	n/a	187.60 mm	202.47 mm	81.39 mm	157.55 mm
Cash remaining	n/a	n/a	863.90 mm	849.04 mm	970.11 mm	893.96 mm
Runway (months of cash)	n/a	n/a	18.5	16.9	47.9	22.8

Beta Read what these cash burn values mean

Financial data from Vaxcyte earnings reports.

Institutional ownership, Q3 2024

PCVX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	328	267	+22.8%
Opened positions	85	47	+80.9%
Closed positions	24	27	-11.1%
Increased positions	127	111	+14.4%
Reduced positions	85	73	+16.4%

13F shares	Current	Prev Q	Change
Total value	14.39 tn	8.67 tn	+66.0%
Total shares	142.43 mm	129.58 mm	+9.9%
Total puts	432.60 k	108.70 k	+298.0%
Total calls	768.40 k	241.70 k	+217.9%
Total put/call ratio	0.6	0.4	+25.2%

Largest owners	Shares	Value	Change
FMR	15.80 mm	$1.81 tn	-2.3%
Vanguard	11.44 mm	$1.31 tn	+16.8%
JHG Janus Henderson	10.92 mm	$1.25 tn	+23.1%
BlackRock	10.67 mm	$1.22 tn	NEW
Ra Capital Management	8.69 mm	$992.91 bn	+5.9%
Capital Research Global Investors	4.90 mm	$559.72 bn	+18.5%
Wellington Management	4.51 mm	$515.79 bn	-1.7%
T. Rowe Price	4.47 mm	$510.35 mm	+40.7%
T. Rowe Price Investment Management	4.05 mm	$463.23 mm	+0.8%
STT State Street	3.41 mm	$389.17 bn	+1.1%

Largest transactions	Shares	Bought/sold	Change
BlackRock	10.67 mm	+10.67 mm	NEW
BLK BlackRock	0.00	-9.94 mm	EXIT
JHG Janus Henderson	10.92 mm	+2.05 mm	+23.1%
Vanguard	11.44 mm	+1.64 mm	+16.8%
T. Rowe Price	4.47 mm	+1.29 mm	+40.7%
Deutsche Bank AG - Registered Shares	1.15 mm	+1.02 mm	+782.8%
Polar Capital	995.78 k	+995.78 k	NEW
Norges Bank	0.00	-984.46 k	EXIT
Clearbridge Advisors	1.16 mm	+973.14 k	+522.8%
Capital Research Global Investors	4.90 mm	+764.68 k	+18.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PCVX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Jan 25	Guggenhime Andrew	Common Stock	Sell	Dispose S	No	Yes	87.7	683	59.90 k	109,491
21 Jan 25	Guggenhime Andrew	Common Stock	Sell	Dispose S	No	Yes	87.247	1,999	174.41 k	110,174
21 Jan 25	Guggenhime Andrew	Common Stock	Sell	Dispose S	No	Yes	86.084	5,318	457.79 k	112,173
21 Jan 25	Guggenhime Andrew	Common Stock	Option exercise	Acquire M	No	No	5.35	8,000	42.80 k	117,491
21 Jan 25	Guggenhime Andrew	Stock Option Common Stock	Option exercise	Dispose M	No	No	5.35	8,000	42.80 k	254,827
15 Jan 25	Teri Loxam	Common Stock	Sell	Dispose S	No	Yes	88.536	529	46.84 k	7,175
15 Jan 25	Teri Loxam	Common Stock	Sell	Dispose S	No	Yes	87.377	1,013	88.51 k	7,704
15 Jan 25	Teri Loxam	Common Stock	Sell	Dispose S	No	Yes	86.257	966	83.32 k	8,717
15 Jan 25	Teri Loxam	Common Stock	Sell	Dispose S	No	Yes	85.293	1,043	88.96 k	9,683
15 Jan 25	Teri Loxam	Common Stock	Sell	Dispose S	No	Yes	83.931	1,202	100.89 k	10,726

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Goldman Sachs Initiates Coverage On Vaxcyte with Buy Rating, Announces Price Target of $135

Goldman Sachs analyst Chris Shibutani initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Buy rating and announces Price Target of $135.

(PCVX) - Analyzing Vaxcyte's Short Interest

(PCVX) - Analyzing Vaxcyte's Short Interest

Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers

Cantor Fitzgerald Reiterates Overweight on Vaxcyte

Press releases

From Benzinga Pro

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ:PCVX) breached their fiduciary duties to

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ:PCVX) breached their fiduciary duties to

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ:PCVX) breached their fiduciary duties to

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.